VIDEO: Dextenza shows promising IOP outcomes in patients with glaucoma

ByNandini Venkateswaran, MD

ByAnthony DeFino

Fact checked byEamon N. Dreisbach

NEW YORK — In this Healio Video Perspective from OSN New York, Nandini Venkateswaran, MD, of Massachusetts Eye and Ear Infirmary, discusses real-world data investigating the use of Dextenza in patients with glaucoma.

Data from more than 10,000 patients was collected using the IRIS registry, with results showing comparable IOP outcomes after implantation with Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) in patients with and without a history of glaucoma.

“Looking at this data with such a large cohort of patients, we can really see that Dextenza is a viable treatment option for patients after surgery for the treatment of ocular pain and inflammation,” she said.

Published by:

Sources/Disclosures

Collapse

Source:

Venkateswaran N. Industry expert theater lunch: Onboard and under your control. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.

Disclosures: Venkateswaran reports consulting for Ocular Therapeutix.

OSN New York and OSN New York Retina

Read more

VIDEO: Dextenza shows promising IOP outcomes in patients with glaucoma

Related Content